Search by Drug Name or NDC
NDC 47783-0645-01 TAKHZYRO 150 mg/mL Details
TAKHZYRO 150 mg/mL
TAKHZYRO is a SUBCUTANEOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is LANADELUMAB.
MedlinePlus Drug Summary
Lanadelumab-flyo injection is used to prevent swelling and painful attacks of hereditary angioedema (HAE; an inherited condition that causes episodes of swelling in the hands, feet, face, airway, or intestines) in adults and children 2 years of age or older. Lanadelumab-flyo is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes swelling and pain associated with HAE.
Related Packages: 47783-0645-01Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Lanadelumab-flyo injection
Product Information
NDC | 47783-0645 |
---|---|
Product ID | 47783-645_7b67bee7-cd75-431e-949e-39399e849426 |
Associated GPIs | |
GCN Sequence Number | 084405 |
GCN Sequence Number Description | lanadelumab-flyo SYRINGE 150 MG/ML SUBCUT |
HIC3 | A7N |
HIC3 Description | PLASMA KALLIKREIN INHIBITORS |
GCN | 53706 |
HICL Sequence Number | 045177 |
HICL Sequence Number Description | LANADELUMAB-FLYO |
Brand/Generic | Brand |
Proprietary Name | TAKHZYRO |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | lanadelumab-flyo |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | SOLUTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 150 |
Active Ingredient Units | mg/mL |
Substance Name | LANADELUMAB |
Labeler Name | Takeda Pharmaceuticals America, Inc. |
Pharmaceutical Class | Kallikrein Inhibitors [MoA], Plasma Kallikrein Inhibitor [EPC] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761090 |
Listing Certified Through | 2024-12-31 |
Package
NDC 47783-0645-01 (47783064501)
NDC Package Code | 47783-645-01 |
---|---|
Billing NDC | 47783064501 |
Package | 1 SYRINGE, GLASS in 1 CARTON (47783-645-01) / 1 mL in 1 SYRINGE, GLASS |
Marketing Start Date | 2023-02-03 |
NDC Exclude Flag | N |
Pricing Information | N/A |